Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084   21/10/2025
5,290 USD (-0,75%)
(-0,75%)   21/10/2025

8 oktober 2025 · Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena · Persbericht

1 oktober 2025 · Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration · Persbericht

25 september 2025 · Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" · Persbericht

28 augustus 2025 · Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences · Persbericht

28 augustus 2025 · Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera · Persbericht

18 augustus 2025 · In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder · Persbericht

31 juli 2025 · Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results · Persbericht

23 juli 2025 · Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 · Persbericht

10 juni 2025 · Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S · Persbericht

27 mei 2025 · Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting · Persbericht

16 mei 2025 · Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 · Persbericht

7 mei 2025 · Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results · Persbericht

5 mei 2025 · Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 · Persbericht

2 mei 2025 · Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 · Persbericht

23 april 2025 · FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA · Persbericht

7 april 2025 · Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting · Persbericht

31 maart 2025 · Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia · Persbericht

11 september 2024 · Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference · Persbericht

4 september 2024 · Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference · Persbericht

29 augustus 2024 · Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference · Persbericht

Mijn selecties